Proto-Oncogene Proteins B-raf
"Proto-Oncogene Proteins B-raf" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A raf kinase subclass found at high levels in neuronal tissue. The B-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2.
| Descriptor ID |
D048493
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.559.842.374 D12.644.360.400.842.374 D12.776.476.400.842.437 D12.776.624.664.700.204.200
|
| Concept/Terms |
Proto-Oncogene Proteins B-raf- Proto-Oncogene Proteins B-raf
- B-raf, Proto-Oncogene Proteins
- Proteins B-raf, Proto-Oncogene
- Proto Oncogene Proteins B raf
- BRAF Kinases
- B-raf Kinases
- B raf Kinases
- Proto-Oncogene Protein B-raf
- B-raf, Proto-Oncogene Protein
- Protein B-raf, Proto-Oncogene
- Proto Oncogene Protein B raf
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins B-raf".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins B-raf".
This graph shows the total number of publications written about "Proto-Oncogene Proteins B-raf" by people in this website by year, and whether "Proto-Oncogene Proteins B-raf" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 3 | 4 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 2 | 3 |
| 2014 | 3 | 2 | 5 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 4 | 5 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 3 | 4 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins B-raf" by people in Profiles.
-
Darp R, Vittoria MA, Ganem NJ, Ceol CJ. Oncogenic BRAF induces whole-genome doubling through suppression of cytokinesis. Nat Commun. 2022 07 15; 13(1):4109.
-
Vittoria MA, Kingston N, Kotynkova K, Xia E, Hong R, Huang L, McDonald S, Tilston-Lunel A, Darp R, Campbell JD, Lang D, Xu X, Ceol CJ, Varelas X, Ganem NJ. Inactivation of the Hippo tumor suppressor pathway promotes melanoma. Nat Commun. 2022 06 29; 13(1):3732.
-
Iesato A, Li S, Roti G, Hacker MR, Fischer AH, Nucera C. Lenvatinib Targets PDGFR-? Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights. J Clin Endocrinol Metab. 2021 11 19; 106(12):3569-3590.
-
Khoshkenar P, Lowry E, Mitchell A. Rapid signaling reactivation after targeted BRAF inhibition predicts the proliferation of individual melanoma cells from an isogenic population. Sci Rep. 2021 07 29; 11(1):15473.
-
Mojtahed SA, Boyer NR, Rao SA, Gajewski TF, Tseng J, Turaga KK. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Ann Surg Oncol. 2021 Dec; 28(13):9039-9047.
-
Hemond CC, Bakshi R, Tauhid S, Sarrosa R, Ryan M, Kamath V, Thomas J, Edwards KR. Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases. J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9:23247096211033047.
-
Janardhan HP, Meng X, Dresser K, Hutchinson L, Trivedi CM. KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition. J Exp Med. 2020 07 06; 217(7).
-
Gupta R, Bugide S, Wang B, Green MR, Johnson DB, Wajapeyee N. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway. Proc Natl Acad Sci U S A. 2019 03 05; 116(10):4583-4591.
-
Bugaj LJ, Sabnis AJ, Mitchell A, Garbarino JE, Toettcher JE, Bivona TG, Lim WA. Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway. Science. 2018 08 31; 361(6405).
-
Yang S, Leone DA, Biswas A, Deng A, Jukic D, Singh R, Sundram U, Mahalingam M. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples. Hum Pathol. 2018 12; 82:206-214.